Trial to Assess Chelation Therapy 2
- 1,200 post-MI patients with diabetes
- 50 yrs or older
- History of diabetes and myocardial infarction
Trial Design: Double-blind, randomized
Intervention: EDTA chelation therapy versus placebo in individuals with coronary artery disease and diabetes
Primary Endpoint: A composite of all-cause mortality, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina
Sponsors: NIH, NHLBI, NCCIH
Daniel B. Mark, MD
TACT2: ECONOMIC STUDY
The specific aim of the economic substudy of the Trial to Assess Chelation Therapy 2 is to perform an economic analysis including a cost-effectiveness assessment of the TACT2 chelation strategy.
Trial is enrolling.
See study website for more information.